AIM ImmunoTech reports Q2 2026 results, cites pancreatic cancer trial progress toward Phase 3
AIM says it finished enrollment and dosing in its Phase 2 pancreatic cancer study and expects survival data in 2027, while cash rose to $9.9 million.
AIM ImmunoTech Inc. reported financial results for the quarter ended June 30, 2026 in an 8-K filed August 10, 2026. The company said it had finished enrolling and dosing patients in its Phase 2 "DURIPANC" study, which is testing Ampligen alongside AstraZeneca's checkpoint inhibitor Imfinzi (durvalumab) in patients with metastatic pancreatic cancer.1
AIM also said it has brought on Thermo Fisher Scientific's PPD clinical research unit to help design a planned pivotal Phase 3 trial in metastatic pancreatic cancer.1 Separately, the company pointed to ongoing findings from Erasmus MC Cancer Institute that it described as showing favorable safety, trends in progression-free and overall survival, and reports of high quality of life among patients treated.1
According to CEO Thomas K. Equels, quoted in the release, AIM anticipates DURIPANC clinical benefit data in the first quarter of 2027 and overall survival data in the third quarter of 2027.1 Equels also stated that the company expects the new data to build on results from Ampligen's Dutch government-approved Named Patient Program in late-stage pancreatic cancer, in which the company reports a median overall survival of 34.8 months versus 12.5 months in historical controls, within a specific immune biomarker patient subset.1 The 8-K notes that, apart from these Equels quotes, the press release exhibit is incorporated by reference into the filing.
On the corporate side, AIM said it regained compliance with NYSE American's continued listing standards.1 It is also preparing government-focused initiatives to study Ampligen's potential against Ebola virus disease, as part of a broader effort to pursue non-dilutive funding for select infectious disease work while keeping pancreatic cancer as its main focus.1
On cash, AIM reported $9.9 million in cash and cash equivalents as of June 30, 2026, up from about $3.0 million at the end of 2025.1 The company said this strengthened financial position supports continued execution of its clinical strategy and upcoming milestones.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.